BNGO vs. DAIO, AXDX, ASTC, STAI, PRPO, TLIS, TBIO, SMIT, SPEC, and THMO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Data I/O (DAIO), Accelerate Diagnostics (AXDX), Astrotech (ASTC), Scantech AI Systems (STAI), Precipio (PRPO), Talis Biomedical (TLIS), Telesis Bio (TBIO), Schmitt Industries (SMIT), Spectaire (SPEC), and ThermoGenesis (THMO). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs.
Bionano Genomics (NASDAQ:BNGO) and Data I/O (NASDAQ:DAIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Data I/O has a net margin of -7.53% compared to Bionano Genomics' net margin of -407.34%. Data I/O's return on equity of -9.05% beat Bionano Genomics' return on equity.
11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 37.0% of Data I/O shares are held by institutional investors. 1.6% of Bionano Genomics shares are held by company insiders. Comparatively, 7.3% of Data I/O shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Bionano Genomics currently has a consensus target price of $62.00, suggesting a potential upside of 1,946.20%. Data I/O has a consensus target price of $4.00, suggesting a potential upside of 70.21%. Given Bionano Genomics' higher possible upside, equities analysts clearly believe Bionano Genomics is more favorable than Data I/O.
In the previous week, Bionano Genomics had 10 more articles in the media than Data I/O. MarketBeat recorded 12 mentions for Bionano Genomics and 2 mentions for Data I/O. Bionano Genomics' average media sentiment score of 0.20 beat Data I/O's score of -0.71 indicating that Bionano Genomics is being referred to more favorably in the media.
Data I/O received 13 more outperform votes than Bionano Genomics when rated by MarketBeat users. Likewise, 66.79% of users gave Data I/O an outperform vote while only 63.78% of users gave Bionano Genomics an outperform vote.
Data I/O has lower revenue, but higher earnings than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Bionano Genomics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Data I/O has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Summary
Data I/O beats Bionano Genomics on 12 of the 18 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 4/6/2025 by MarketBeat.com Staff
Buy BNGO Stock Free BNGO Stock Alerts